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Objective
To assess the effectiveness and functional capacity with
rheumatoid artritis treated with biologic after dose
reduction.
Methods
A retrospective study on a cohort of 13 patients diagnosed
rheumatoid artritis treated with anti-TNF (10 patients
with etanercept, and 3 with adalimumab) and clinical
remission (DAS28 < 2.6) in the last 6 mounths, in which
reducing the dosing. Clinical activity was evaluated by clin-
ical activity index (DAS28), for functional capacity was
used HAQ (Health Assessment Questionnaire). Others
variables studied was visual analog scale (VAS). Analyzing
before starting dose reduction, at 3 and 6 months.
Results
The study includes 13 patients, 12 female, with RF in 90%
and erosions in 40%, treated with etanercept 10 and ada-
limumab 3. More of them (85%) had recieved at least 2
FAMES before biological. Dose reduction in the etaner-
cept group was 2 weekly injections to one injection every
5 days. In the case of adalimumab the pattern used was
an injection every 20 days.
Of the 10 patients treated with etanercept 4 returned
to their usual pattern, as well as 2 of the 3 patients with
Adalimumab.
Conclusions
The reduction of etanercept and adalimumab doses in
patients with rheumatoid arthritis in clinical remission
(DAS28 <2.6) appears to be effective, since it manages
to keep the DAS28 and the VAS. Not so the HAQ in
which if there are significant differences that support
that after the patient expresses reduce doses higher
score on the test. Although the results 6 of 13 patients
(46.2%) return to your regular schedule by mutual self-
referred as subjectively feel worse and increase in sei-
zures of exacerbation.
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Table 1
BASELINE 3 MONTHS 6 MONTHS INFERENCE
VAS (mm) 23,08±17,02 29,31±18,69 23,50±16,33 p = 0,670
HAQ 0,69±0,59 0,85±0,61 0,76±0,69 p = 0,001
DAS28 2,24±0,36 2,64±0,85 2,65±0,58 p = 0,51
Martínez-Pérez et al. Journal of Translational Medicine 2011, 9(Suppl 2):P44
http://www.translational-medicine.com/content/9/S2/P44
© 2011 Martínez-Pérez et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.